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INTRODUCTION: We report a patient with a rapidly progressing recurrence of hepatocellular carcinoma
(HCC)with a portal vein tumor thrombus after radiofrequency ablation of the original lesion, then treated
with transcatheter arterial infusion. Radical hepatic resection demonstrated a complete pathological
response.
PRESENTATIONOFCASE:A60-yearoldmalewithalcoholic cirrhosis andgastric variceswasdiagnosedwith
HCC measuring 12mm in segment 8. He underwent laparoscopic radiofrequency ablation, but recurred
three months later. The lesion progressed rapidly and the right portal vein was occluded. He then under-
went transcatheter arterial infusion with miriplatin and iodized oil, which was effective in reducing the
sizeof themain lesionandportal vein tumor thrombus.Right anterior sectionectomywas thenperformed.
Pathologically, there were no viable HCC cells in either the main lesion or the portal vein thrombus. He
is alive two years and nine months after surgery without recurrence.
DISCUSSION:A rapidly progressingHCC recurrencewith portal vein tumor thrombus is usually associated
with a poor prognosis. No effective treatments have been reported in this situation except hepatic resec-
tion. In this patient the tumor was effectively reduced after three courses of transarterial miriplatin and
subsequent radical hepatic resection. This is the ﬁrst report to achieve a complete pathological response
for such an aggressive recurrence after initial radiofrequency ablation.
CONCLUSION:This strategymay result in long-termsurvival of patientswith rapidlyprogressing recurrent
HCC with portal vein thrombus, and further study is warranted.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Radiofrequency ablation (RFA) for small hepatocellular carci-
nomas (HCC) is minimally invasive, has good efﬁcacy and is often
used as ﬁrst line therapy [1]. Rapidly progressive recurrence of HCC
after RFA has also been reported [2]. If recurrence is accompanied
by portal vein tumor thrombus, it generally progresses so rapidly
as to be untreatable. We report a patient with a rapidly progressive
recurrent HCC with portal vein thrombus after RFA, treated with
Abbreviations: HCC, hepatocellular carcinoma;RFA, radiofrequencyablation; CT,
computed tomography; TAI, transcatheter arterial infusion; AFP, alpha-fetoprotein;
PIVKA-II, protein induced by vitamin K antagonist-II.
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transcatheter arterial infusion. Radical hepatic resection was then
performed which demonstrated a complete pathological response
to the therapy.
2. Presentation of case
A 60-year old man with alcoholic liver cirrhosis and gastric
varices was found to have an elevated serum alpha-fetoprotein
(AFP) to 13ng/ml and protein induced by vitamin K antagonist-II
(PIVKA-II) level of 391mAU/ml. He underwent contrast enhanced
computed tomography (CT) scan which showed a 12mm tumor
which enhanced in the arterial phase and washed out in the equi-
libriumphase in segment8, consistentwithHCC (Fig1). Coreneedle
biopsy of the lesion showed moderately differentiated hepatocel-
lular carcinoma that was treated using laparoscopic RFA.
The tumor recurred three months later while we were planning
further therapy and progressed rapidly. The right portal vein was
totally occluded 144 days after RFA (Fig 2). We initially planned a
http://dx.doi.org/10.1016/j.ijscr.2015.03.015
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Contrast enhanced CT scan shows an enhancing 12mm tumor in the arterial phase (arrow) and wash-out in the equilibrium phase (arrowhead), consistent with an
HCC in segment 8.
Fig. 2. Enhanced CT scan in the arterial phase shows an enhancing recurrent tumor (upper; arrow) and a relatively hypervascular area due to portal vein thrombus. In the
equilibrium phase, the main tumor was washed-out (lower; arrow) and a right portal vein was totally occluded by a tumor thrombus (arrowhead).
radical right hepatectomy, but postponed the procedure while the
patient was treated using transcatheter arterial infusion (TAI). The
ﬁrst TAI treatment was given 146 days after RFA, using miriplatin
120mg and iodized oil 11ml through an anterior sectional branch
of the right hepatic artery (A5/A8) and conﬁrmed accumulation of
iodized oil in the main lesion and portal vein thrombus (Fig 3).
Peak AFP and PIVKA-II were 139ng/ml and 8201mAU/ml respec-
tively at 172 days after RFA, and they then decreased. A second
TAI treatment was performed with miriplatin 140mg and iodized
oil 8ml through the same artery at 180 days after RFA. At 251
days after RFA, a third treatment was given. Angiography demon-
strated a large arterial-portal shunt in the tumor with drainage
to the para-umbilical veins. Based on this, we then administered
miriplatin 140mg through the right hepatic artery without iodized
oil. At 265 days after RFA, a contrast enhanced CT scan showed a
marked decrease in size of the main lesion and recanalization of
the posterior sectional branch of right portal vein (Fig 4).
At that time, the patient’s liver function was classiﬁed as Child-
Pugh A (score =5), and the indocyanine green 15min retention test
was 12.1%. A right anterior sectionectomy was then performed
at 280 days after RFA. Macroscopic ﬁndings showed coagulation
necrosis at the tumor site. Microscopically, there were no viable
tumor cells at the tumor site. Collapse of the liver parenchyma and
organization of the thrombus in the portal vein were found with
no malignant cells (Fig 5). The patient is alive two years and nine
months after surgery without evidence of recurrence.
3. Discussion
In this patient, a rapidly progressing recurrent HCC with por-
tal vein thrombus after RFA markedly reduced in size after TAI
treatment with miriplatin and iodized oil. Subsequently, radical
resection was safely performed. This is the ﬁrst report to demon-
strate a complete pathological response of a main tumor lesion and
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Fig. 3. The ﬁrst TAI treatmentwas done through an injection in the anterior sectional branch of the right hepatic artery (A5/A8). At the same time,we conﬁrmed accumulation
of iodized oil in the main lesion and portal vein tumor thrombus with plain CT imaging (arrowhead).
Fig. 4. Enhanced CT scan in the portal phase shows a markedly decrease in size of the main lesion (arrow) and portal vein tumor thrombus. The posterior sectional branch
of right portal vein was recanalized (arrowhead).
portal vein thrombus that underwent aggressive growth of recur-
rent disease following RFA.
RFA for early small HCC lesions is minimally invasive with gen-
erally good results and is often used as a ﬁrst line local therapy [1].
However, rapidly progressive recurrence of HCC lesions after RFA
has been reported [2]. The mechanism for the rapid growth has
been hypothesized to be dedifferentiation that increases themalig-
nant potential of residual tumor cells [2–4]. The RFA needle creates
a path along its track between the tumor site and portal veins,
which may increase intra-tumor pressure by thermal coagulation,
resulting in dissemination of tumor into the portal veins [2,4,5].
Yamada, et al. reported that local recurrence of HCC after RFA has
a high frequency of portal venous invasion [6]. The incidence of
rapidly progressive recurrence of HCC after RFA has been reported
to be 0.1–4.5% [7–9]. If portal tumor thrombus is accompanied by
recurrence, progression of recurrent lesions may accelerate.
Previous reports describe seven patients with rapidly pro-
gressing HCC with portal vein thrombus following RFA (Table 1)
[10–14]. The time to recurrence following RFA was short (one to
six months). Five patients had ﬁrst-order branch of the portal vein
tumor thrombi and underwent TAI and systemic chemotherapy
after recurrence. They all died shortly after treatment [11,12,14].
Two patients developed second-order portal vein branch tumor
thrombi and underwent radical resection [10,13]. In this situation,
the prognosis is poor, but combination therapy including hepatic
resection may improve the prognosis. However, resection of HCC
with tumor thrombi in the main portal vein is often accompanied
by increased risk and associated with a 6–12% postoperative mor-
tality [15,16]. In this patient, treatment reduced the size of the right
portal vein thrombus into only the anterior sectional branch, and
radical right anterior sectionectomy could be performed. This was
an effective strategy to down-stage the tumor and enable a radical
resection.
TAI does not employ embolic materials so it is a safe procedure
for patients with advanced portal vein thrombi. We observed a
marked antitumor effect with a complete pathological response
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Table 1
Previous reports of rapidly progressing hepatocellular carcinoma with portal vein tumor thrombus after radiofrequency ablation
Series (Ref.) Author
(year)
Age/gender Etiology Site Size (mm) Time to
recurrence
after RFA
Portal invasion
after
recurrence
Therapy after
recurrence
Outcome
1
[10]
Katagiri 2003 34/M HBV S7 22 5M Second-order branch Right posterior
sectionectomy
13M alive
2
[11]
Takada 2003 68/F HCV S7 27 4M First-order branch TAI 4M death
3
[11]
64/M HBV S6 and S8 16 and 18 6M First-order branch None 2M death
4
[12]
Portolani 2003 66/F HCV S4 20 3M First-order branch Systemic
chemotherapy
2M death
5
[13]
Izai 2005 71/M HCV S5 and S6 20 and 20 1M Second-order branch Right hepatectomy 16M alive
6
[14]
Fushiya 2011 78/M Alcohol S5/8 30 4M First-order branch None 5M death
7
[14]
67/M HCV S6 30 4M First-order branch Systemic
chemotherapy
(5-FU p.o.)
5M death
8 Present case 60/M Alcohol S8 12 3M First-order branch TAI (Miriplatin)
→Right anterior
sectionectomy
40M alive
RFA, radiofrequency ablation; TAI, transcatheter arterial infusion.
Fig. 5. Macroscopic ﬁndings showed a yellowish tumor in the liver (arrow) and an
18mm-sized whitish area adjacent to it (arrowhead). Microscopic ﬁndings showed
collapse of the liver parenchyma (upper; a part of arrow, H.E. stain×4), coagulation
necrosis of the tumor (middle; a part of arrowhead, H.E. stain×4) and organized
thrombus in the portal vein (lower; Elastica van Gieson stain×4). All areas had no
viable tumor cells.
following intra-arterial therapy. There are a number of possible
effects which may have contributed to this outcome including:
(1) The tumor had an abundant arterial blood supply due to the
reduction in portal ﬂow caused by the tumor thrombus. (2) The
tumor was very sensitive to miriplatin. (3) Repeated TAI was pos-
sible because the drug was well tolerated without obvious liver
damage. The drugwas injected into the anterior sectional branch of
the right hepatic artery aiming at a relatively broad area. Therefore,
iodized oil accumulated not only in the main tumor mass, but also
went to the portal vein thrombus leading to an improved antitumor
effect. It is likely that there was no major accumulation of iodized
oil in the portal vein thrombus, and control of the main lesion may
have contributed to the reduction in size of the tumor thrombus.
Transcatheter arterial chemoembolization [17,18] or IFN-/5-FU
combination therapy [19,20] have been reported to be effective in
the treatment of advanced portal vein thrombi due to HCC. Yet
these therapies may not be effective in patients with recurrence
after RFA, which has unique factors such as phenotypic transfor-
mation or portal dissemination of the tumor. Further studies are
required to determine which strategy is most suitable for the por-
tal vein tumor thrombi developing as a result of rapidly progressing
recurrence after RFA.
Development of an arterial-portal shunt after TAI is a dif-
ﬁcult complication. Portal vein tumor thrombi may cause an
arterial-portal shunt due to arterial feeding, which decreases the
effectiveness of TAI therapy and limits imaging of the main tumor,
making it difﬁcult to continue TAI. A large arterial-portal shunt
can result in portal hypertension, making surgical resection more
complicated. Surgery should be considered before the develop-
ment of an arterial-portal shunt that may cause deterioration in
the patient’s condition.
4. Conclusions
We successfully performed TAI and subsequent radical hepatic
resection in apatientwith a rapidly progressing recurrentHCCwith
portal vein tumor thrombus, which developed after RFA. A remark-
able antitumor effect with a complete pathological response was
obtained, suggesting that TAI may play an important role in the
treatment of this condition. Further studies are required to develop
this strategy further for patients with HCC.
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